Back to News
Market Impact: 0.35
Clene Seeks FDA Clearance For CNM-Au8 Following ALS Clinical Research
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Clene Inc. submitted an NDA to the FDA earlier in October seeking accelerated approval of CNM-Au8 to treat amyotrophic lateral sclerosis (ALS). The filing is a regulatory milestone; the article does not report an FDA decision or additional trial or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
CLNN0.70
More News
- ’Panic’ selling hits Indonesian markets on MSCI expulsion threat
- Egyptian parliament delays vote on military support for Saudi Arabia
- DeepSeek deep-sixed at all US federal civilian agencies
- We're buying more of a beaten-up stock before another overhang is lifted
- Crushed tech stocks bounce — plus, new doctor survey keeps us positive on Lilly
- Capital One, General Motors are among the stocks reporting this week with momentum. Here are the others
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AlphaSense vs Hebbia vs AllMind: Choose by Workflow
- AllMind Discusses Ontario's AI Economy with Minister Stephen Crawford and Supply Ontario CEO James Wallace